Mabletown, GA — June 4, 2026 — White Fox Ventures, Inc. (OTCExpertMarkets: AWAW), a subsidiary of Embarr Downs, Inc. (OTCID: EMBR), Acquires Controlling Interest in ReGenTA (“ReGenTA”), a North Carolina-based regenerative health and wellness platform founded and led by Dr. Timothy Gant and Dr. April Gant.
The acquisition marks White Fox and by extension, Embarr Downs’ entry into the regenerative medicine sector.
ReGenTA is evolving from a stem cell clinic into a hybrid regenerative medicine company with biotech ambitions, focused on developing and validating next-generation therapies for major unmet medical needs. Building on its established clinical platform, ReGenTA will continue delivering patient-centered wellness and regenerative services while expanding its role in translational research, clinical validation, and advanced cell-based care. The company’s long-term vision is to help bridge the gap between academic discovery and practical, evidence-based therapies that support repair, restoration, and improved patient outcomes.
Looking beyond this initial footprint, Embarr Downs intends to aggressively scale the platform by opening additional regenerative medicine centers across key markets. The Company believes the next major shift in medicine will come from treatments that do more than manage symptoms, but instead help repair, restore, and regenerate damaged tissues. Stem cell and cell-based therapies are already being studied across a wide range of conditions, from diabetes and cardiovascular disease to neurological disorders and organ repair. Ultimately, the Company aims to establish strategic partnerships with leading regenerative medicine universities to accelerate the development of evidence-based regenerative therapies, improve patient outcomes, and expand the possibilities of modern medicine. By combining clinical expertise, translational research, and advanced cell-based platforms, Embarr Downs aims to move promising science from the lab directly into meaningful patient care.
For several years, ReGenTA has delivered clinical wellness, IV therapy, home care, and regenerative medicine consultations. ReGenTA is an established, operating platform — not a development-stage concept — and it gives Embarr Downs an operating foundation from which to build in regenerative health and wellness, a fragmented category dominated by independent providers.
Following the closing, Dr. Timothy Gant and Dr. April Gant will continue to lead ReGenTA’s clinical operations, and Mark Jones, President and CEO of Embarr Downs, will oversee platform integration.
A STRATEGIC ENTRY INTO REGENERATIVE MEDICINE
Regenerative medicine is an area of growing clinical and research interest. With this acquisition, Embarr Downs intends to build a premier regenerative health and wellness platform anchored by ReGenTA’s existing clinical operations, applying the Company’s consolidation model — centralized operations, brand development, and patient-acquisition infrastructure — to support and scale ReGenTA’s team.
With the Company’s support, ReGenTA is expanding into its first full-scale Stem Cell & Regenerative Medicine Center. The expanded center is intended to offer clinical services, IV therapy, mental wellness services, hyperbaric oxygen therapy, red light therapy, peptide therapies, and longevity optimization services, alongside ReGenTA’s existing regenerative medicine consultations.
This foundational center represents the baseline for a broader expansion strategy. By bridging the gap between academic research and commercial clinical settings, the Company’s long-term roadmap focuses on fostering collaborative university partnerships to validate and deploy next-generation cell-based therapies safely and effectively.
MANAGEMENT COMMENTARY
“ReGenTA gives us a real operating foundation in a sector we believe in,” said Mark Jones, President and CEO of Embarr Downs. “Dr. Timothy Gant and Dr. April Gant have built an exceptional, clinician-led practice over several years. Our role is to not only support their team and scale operations responsibly by opening more centers, but to position Embarr Downs at the intersection of clinical care and academic research. By partnering with regenerative medicine universities, we intend to help bridge the gap between translational research and practical, evidence-based therapies that truly advance modern medicine and enhance patient outcomes.”
ABOUT REGENTA
ReGenTA is a North Carolina-based regenerative health and wellness platform founded and led by Dr. Timothy Gant and Dr. April Gant, providing clinical wellness, IV therapy, home care, and regenerative medicine consultations. ReGenTA is evolving into a hybrid regenerative medicine company with biotech ambitions, focused on developing and validating next-generation therapies for major unmet medical needs.
About White Fox Ventures, Inc.
White Fox Ventures, Inc. (OTCMarkets: AWAW) is a diversified holdings and venture development firm specializing in the acquisition, restructuring, and scaling of undervalued or emerging private companies. The Company’s mandate is to identify overlooked opportunities across high-growth sectors and transform them into high-performing, shareholder-value-generating assets through capital infusion, executive leadership, operational modernization, and disciplined strategic execution. White Fox targets companies with strong underlying potential that lack access to capital, institutional infrastructure, or experienced management — partnering with founders and operators to unlock that potential at scale.
White Fox’s core focus sectors are:
ABOUT EMBARR DOWNS, INC.
Embarr Downs, Inc. (OTCID: EMBR) is a consolidation platform that acquires operating businesses in fragmented categories and standardizes their operations on a technology-enabled platform. For more information, contact info@whitefoxventures.com.
Safe Harbor Statement
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements may be identified by the use of words including “may,” “will,” “should,” “plans,” “expects,” “anticipates,” “estimates,” “projects,” “intends,” and similar expressions. Forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from those projected or anticipated. These risks and uncertainties include, but are not limited to, the Company’s ability to successfully execute its expanded business strategy; general economic and business conditions; effects of geopolitical unrest and regional conflicts; competition; changes in technology and methods of marketing; changes in customer order patterns and product mix; regulatory requirements; government agency rules and changes; and various other factors beyond the Company’s control. White Fox Ventures undertakes no obligation to update or revise any forward-looking statements to reflect events or circumstances that arise after the date of this release.
NO OFFER OF SECURITIES
This press release is for informational purposes only and does not constitute an offer to sell or a solicitation of an offer to buy any security. Any securities offering by the Company will be made only through definitive offering materials and in accordance with applicable securities laws.
REGULATORY NOTE — REGENERATIVE HEALTH SERVICES
Certain services offered or planned by ReGenTA — including stem cell–based therapies, peptide therapies, and other regenerative treatments, as well as services such as hyperbaric oxygen therapy used outside their FDA-cleared indications — are not approved by the U.S. Food and Drug Administration (FDA) for many of the uses for which such therapies are commonly marketed. Statements in this release describe the services ReGenTA offers or plans to offer, are not intended to diagnose, treat, cure, or prevent any disease, and have not been evaluated by the FDA.
Media & Investor Contact
White Fox Ventures, Inc. (OTCMarkets: AWAW)
Embarr Downs, Inc. (OTCID: EMBR)
Email: info@whitefoxventures.com